Hostname: page-component-7c8c6479df-995ml Total loading time: 0 Render date: 2024-03-28T17:36:51.944Z Has data issue: false hasContentIssue false

Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk

Published online by Cambridge University Press:  02 January 2007

Esther C Janowsky*
Affiliation:
Department of EpidemiologyUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Gayle E Lester
Affiliation:
Department of Orthopedic SurgeryUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Clarice R Weinberg
Affiliation:
National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
Robert C Millikan
Affiliation:
Department of EpidemiologyUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Joellen M Schildkraut
Affiliation:
Office of Cancer Prevention and Control, Duke University Medical Center, Durham, NC 27710, USA
Peter A Garrett
Affiliation:
Department of EpidemiologyUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Barbara S Hulka
Affiliation:
Department of EpidemiologyUniversity of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
*
*Corresponding author: Email esther_janowsky@unc.edu
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective

To determine if blood levels of 25-hydroxyvitamin D (25-D) or its active metabolite, 1,25-dihydroxyvitamin D (1,25-D), are lower in women at the time of first diagnosis of breast cancer than in comparable women without breast cancer.

Design

This was a clinic-based case–control study with controls frequency-matched to cases on race, age, clinic and month of blood drawing.

Setting

University-based breast referral clinics.

Subjects

One hundred and fifty-six women with histologically documented adenocarcinoma of the breast and 184 breast clinic controls.

Results

There were significant mean differences in 1,25-D levels (pmol ml−1) between breast cancer cases and controls; white cases had lower 1,25-D levels than white controls (mean difference ± SE: −11.08 ± 0.76), and black cases had higher 1,25-D levels than black controls (mean difference ± SE: 4.54 ± 2.14), although the number of black women in the study was small. After adjustment for age, assay batch, month of blood draw, clinic and sample storage time, the odds ratio (95% confidence interval, CI) for lowest relative to highest quartile was 5.2 (95% CI 2.1, 12.8) for white cases and controls. The association in white women was stronger in women above the median age of 54 than in younger women, 4.7 (95% CI 2.1, 10.2) vs. 1.5 (95% CI 0.7, 3.0). There were no case–control differences in 25-D levels in either group.

Conclusions

These data are consistent with a protective effect of 1,25-D for breast cancer in white women.

Type
Research Article
Copyright
Copyright © CABI Publishing 1999

References

1DeLuca, HF, Ostrem, V. The relationship between the vitamin D system and cancer. Adv. Exp. Med. Biol. 1987; 206: 413–29.Google Scholar
2Reichel, H, Koeffler, HP, Norman, AW. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 1989; 320: 980–91.CrossRefGoogle ScholarPubMed
3Manoglas, SC. Vitamin D and its relevance to cancer. AntiCancer Res. 1987; 7: 625–38.Google Scholar
4Studzinski, GP, Moore, DC. Sunlight—can it prevent as well as cause cancer? Cancer Res. 1995; 55: 4014–22.Google ScholarPubMed
5Gorham, ED, Garland, FC, Garland, CF. Sunlight and breast cancer incidence in the USSR. Int. J. Epidemiol. 1990; 19: 820–4.CrossRefGoogle ScholarPubMed
6Garland, FC, Garland, CF, Gorham, ED, Young, JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 1990; 19: 614–22.CrossRefGoogle ScholarPubMed
7Blot, WJ, Fraumeni, JF, Stone, BJ. Geographic patterns of breast cancer in the United States. J. Natl. Cancer Inst. 1977; 59: 1407–11.CrossRefGoogle ScholarPubMed
8Simard, A, Vobecky, J, Vobecky, JS. Vitamin D deficiency and cancer of the breast: an unprovocative ecological hypothesis. Can. J. Public Health 1991; 82: 300–3.Google ScholarPubMed
9Chouvet, C, Vicard, E, Devonec, M, Saez, S. 1,25-dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J. Steroid Biochem. 1986; 24: 373–6.CrossRefGoogle ScholarPubMed
10Frappart, L, Falette, N, Lefebvre, MF, Bremond, A, Vauzelle, JL, Saez, S. In vitro studies of effects of 1,25-dihydroxyvitamin D3 on the morphology of human breast cancer cell line BT-20. Differentiation 1989; 40: 63–9.Google Scholar
11Welsh, J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell Biol. 1994; 72: 537–47.CrossRefGoogle ScholarPubMed
12James, SY, Mackay, AG, Colston, KW. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J. Mol. Endocrinol. 1995; 14: 391–4.CrossRefGoogle ScholarPubMed
13Tsoukas, CD, Provvedini, DM, Manolagas, SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984; 224(4656): 1438–40.CrossRefGoogle ScholarPubMed
14Reinhardt, TA, Ramberg, CF, Horst, RL. Comparison of receptor binding, biological activity, and in vivo tracer kinetics for 1,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D2, and its 24 epimer. Arch. Biochem. Biophys. 1989; 273: 6471.Google Scholar
15Nemere, I, Yoshimoto, Y, Norman, AW. Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D3. Endocrinology 1984; 115: 1476–83.CrossRefGoogle ScholarPubMed
16Krishnan, AV, Feldman, D. Stimulation of 1,25-dihydroxyvitamin D3 receptor gene expression in cultured cells by serum and growth factors. J. Bone Miner. Res. 1991; 6: 1099–107.CrossRefGoogle ScholarPubMed
17Love, RR, Mazess, RB, Barden, HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 1992; 326: 852–6.CrossRefGoogle Scholar
18Holick, MF. The use and interpretation of assays for vitamin D and its metabolites. J. Nutr. 1990; 120: 1464–9.CrossRefGoogle ScholarPubMed
19Mawer, EB, Walls, J, Howell, A, Davies, M, Ratcliffe, WA, Bundred, NJ. Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer with bone metastases. J. Clin. Endocrinol. Metab. 1997; 82: 118–22.Google ScholarPubMed
20Elledge, RM, Clark, GM, Chamness, GC, Osborne, CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl. Cancer Inst. 1994; 86: 705–12.CrossRefGoogle ScholarPubMed
21Abrams, SA, O'Brien, KO, Liang, LK, Stuff, JE. Differences in calcium absorption and kinetics between black and white girls aged 5–16 years. J. Bone Miner. Res. 1995; 10: 829–33.CrossRefGoogle ScholarPubMed
22Meier, DE, Luckey, MM, Wallenstein, S, Clemens, TL, Orwoll, ES, Waslien, CI. Calcium, vitamin D, and parathyroid hormone status in young white and black women: association with racial differences in bone mass. J. Clin. Endocrinol. Metab. 1991; 72: 703–10.CrossRefGoogle Scholar
23M'Buyamba-Kabangu, JR, Fagard, R, Lijnen, P, Bouillon, R, Lissens, W, Amery, A. Calcium, vitamin D–endocrine system, and parathyroid hormone in black and white males. Calcif. Tissue Int. 1987; 41: 70–4.CrossRefGoogle ScholarPubMed
24Reasner, CA, Dunn, JF, Fetchik, DA, et al. Alteration of vitamin D metabolism in Mexican-Americans. J. Bone Miner. Res. 1990; 5: 1317.CrossRefGoogle ScholarPubMed
25Bell, NH, Greene, A, Epstein, S, Oexmann, MJ, Shaw, S, Shary, J. Evidence for alteration of the vitamin D–endocrine system in blacks. J. Clin. Invest. 1985; 76: 470–3.CrossRefGoogle ScholarPubMed
26Loomis, F. Skin-pigment regulation of vitamin D biosynthesis in man. Science 1967; 157: 501–6.CrossRefGoogle ScholarPubMed
27Hiatt, RA, Krieger, N, Lobaugh, B, Drezner, MK, Vogelman, JH, Orentreich, N. Prediagnostic serum vitamin D and breast cancer. J. Natl. Cancer Inst. 1998; 90: 461–3.CrossRefGoogle ScholarPubMed
28Garrett, PA, Hulka, BS, Kim, YL, Farber, RA. HRAS proto-oncogene polymorphism and breast cancer. Cancer Epidemiol. Biomark. Prev. 1993; 2: 131–8.Google ScholarPubMed
29Hosmer, DW, Lemeshow, S. Applied Logistic Regression. New York: John Wiley & Sons, 1989.Google Scholar
30SAS Companion for the Microsoft Windows Environment, version 6. Cary, NC: SAS Institute Inc., 1993.Google Scholar
31Breslow, NE, Day, NE. Statistical Methods in Cancer Research, Vol. I. The Analysis of Case–Control Studies. Lyon: International Agency for Research on Cancer, 1980.Google Scholar
32Harris, JR, Lippman, ME, Veronesi, U, Willet, W. Breast cancer. N. Engl. J. Med. 1992; 327: 319–28.CrossRefGoogle ScholarPubMed
33Bouillon, RA, Auwerx, JH, Lissens, WD, Pelemens, WK. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-hydroxyvitamin cholecalciferol deficiency. Am. J. Clin. Nutr. 1987; 45: 755–63.CrossRefGoogle Scholar
34Sherman, SS, Hollis, BW, Tobin, JD. Vitamin D status and related parameters in a healthy population: the effects of age, sex, and season. J. Clin. Endocrinol. Metab. 1990; 71: 405–13.CrossRefGoogle Scholar
35Cantatore, FP, Carrozzo, M, Magle, DM, D'Amore, M, Pipitone, V. Serum 1,25(OH)2D in the elderly and osteoporotic subjects from southern Italy. In: Norman, AW, Schafer, K, Grigoleit, H-G, Herrath, DV, eds. Vitamin D: Molecular, Cellular and Clinical Endocrinology. Proceedings of the Seventh Workshop on Vitamin D. New York: Walter de Gruyter & Co., 1988; 897–8.CrossRefGoogle Scholar
36Halloran, BP, Portale, AA, Lonergan, ET, Morris, RC Jr. Production and metabolic clearance of 1,25-dihydroxyvitamin D in men: effect of advancing age. J. Clin. Endocrinol. Metab. 1990; 70: 318–23.CrossRefGoogle ScholarPubMed
37Tsai, KS, Wahner, HW, Offord, KP, Melton, LJ III, Kumar, RRiggs, BL. Effect of aging on vitamin D stores and bone density in women. Calcif. Tissue Int. 1987; 40: 241–3.CrossRefGoogle ScholarPubMed
38Gloth, FM III, Gundberg, CM, Hollis, BW, Haddad, JG, Tobin, JD. Vitamin D deficiency in homebound elderly persons. JAMA 1995; 274: 1683–6.CrossRefGoogle ScholarPubMed
39Leaver, DD, Trechsel, U, Fleisch, H. How is plasma 1,25(OH)2D3 concentration regulated by dietary calcium? In: Norman, AW, Schafer, K, Grigoleit, H-G, Herrath, DV, eds. Vitamin D: Molecular, Cellular and Clinical Endocrinology. Proceedings of the Seventh Workshop on Vitamin D. New York: Walter de Gruyter & Co., 1988; 662–3.CrossRefGoogle Scholar
40Weiss, NS, Liff, JM. Accounting for the multicausal nature of disease in the design and analysis of epidemiologic studies. Am. J. Epidemiol. 1983; 117: 1418.CrossRefGoogle ScholarPubMed
41Webb, R, Pilbeam, C, Hanafin, N, Holick, M. An evaluation of the relative contribution of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am. J. Clin. Nutr. 1990; 51: 1075–81.CrossRefGoogle Scholar
42Tsai, KS, Heath, H III, Kumar, R, Riggs, BL. Impaired vitamin D metabolism with aging in women. J. Clin. Invest. 1984; 73: 1668–72.CrossRefGoogle ScholarPubMed
43Colston, KW, Berger, U, Coombes, RC. Possible role for vitamin D in controlling breast cell proliferation. Lancet 1989: 1: 188–91.Google Scholar
44Lieberman, UA. Inborn errors in vitamin D metabolism—their contributions to the understanding of vitamin D metabolism. In: Norman, AW, Schafer, K, Grigoleit, H-G, Herrath, DV, eds. Vitamin D: Molecular, Cellular and Clinical Endocrinology. Proceedings of the Seventh Workshop on Vitamin D. New York: Walter de Gruyter & Co., 1988; 935–47.CrossRefGoogle Scholar
45Taylor, JA, Hirvonen, A, Watson, M, Pittman, G, Mohler, JL, Bell, DA. Association of, prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996; 56: 4108–10.Google ScholarPubMed
46Ikekawa, N. Structures and biological activities of vitamin D metabolites and their analog. Med. Res. Rev. 1987; 7: 333–66.Google Scholar
47Matsumoto, T. Cell differentiation and vitamin D. Nippon Naibunpi Gakki Zasshi 1992; 68(5): 526–37.Google ScholarPubMed
48Mehta, RG, Moriarty, RM, Mehta, RR, et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1a-hydroxyvitamin D5. J. Natl. Cancer. Inst. 1997; 89: 212–18.CrossRefGoogle Scholar